FSD Pharma (FSD Pharma) Total Current Liabilities : $4.57 Mil (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

What is FSD Pharma Total Current Liabilities?

Total current liabilities includes Accounts Payable & Accrued Expense, Short-Term Debt & Capital Lease Obligation, Other Current Liabilities, and Current Deferred Liabilities. FSD Pharma's total current liabilities for the quarter that ended in Dec. 2023 was $4.57

FSD Pharma Total Current Liabilities Historical Data

The historical data trend for FSD Pharma's Total Current Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

FSD Pharma Total Current Liabilities Chart

FSD Pharma Annual Data

Trend Aug15 Aug16 Aug17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23

Total Current Liabilities

Get a 7-Day Free Trial 6.83 5.58 8.70 7.83 4.57

FSD Pharma Quarterly Data

Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23

Total Current Liabilities Get a 7-Day Free Trial 7.83 8.60 5.85 4.20 4.57

FSD Pharma Total Current Liabilities Calculation

Total Current Liabilities is the total amount of liabilities that the company needs to pay over the next 12 months.

FSD Pharma's Total Current Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 4.195 + 0.339

+ Other Current Liabilities + Current Deferred Liabilities

= 0.031999999999999 + 0

= 4.57

FSD Pharma's Total Current Liabilities for the quarter that ended in Dec. 2023 is calculated as

Total Current Liabilities = Accounts Payable & Accrued Expense + Short-Term Debt & Capital Lease Obligation

= 4.195 + 0.339

+ Other Current Liabilities + Current Deferred Liabilities

= 0.031999999999999 + 0

= 4.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The increase of Total Current Liabilities of a company is not necessarily a bad thing. This may conserve the company's cash and contribute positively to cash flow.

Total Current Liabilities is linked to Total Current Assets through the Current Ratio and Working Capital. The Current Ratio is equal to dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations. Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Be Aware

Stay away from companies that roll over the debt e.g. Bear Stearns

When investing in financial institutions, Buffett shies from those who are bigger borrowers of short term than long term debt.

His favorite Wells Fargo has 57 cents short term debt for every dollar of long term.

Aggressive banks (like Bank of America) has $2.09 short term for every dollar long term

FSD Pharma Total Current Liabilities Related Terms
Thank you for viewing the detailed overview of FSD Pharma's Total Current Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

FSD Pharma (FSD Pharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » FSD Pharma Inc (NAS:HUGE) » Definitions » Total Current Liabilities

Comparable Companies

TSXV:DB TSX:CWEB TSX:MDP TSXV:ZYUS XCNQ:MMEN XCNQ:CXXI XCNQ:GRIN TSX:AVNT XCNQ:ACRG.A.U XCNQ:GDNS ZTS XTER:MRK TSE:4502 LSE:HLN NSE:SUNPHARMA TSE:4523 TSE:4507 SZSE:000538 XSWX:SDZ HKSE:03692

Traded in Other Exchanges

0K9:Germany HUGE:Canada

Address

199 Bay Street, Suite 4000, Toronto, ON, CAN, M5L 1A9

Website

https://www.fsdpharma.com

FSD Pharma Inc is a biopharmaceutical company developing three clinical candidates with the potential to address neuropsychiatric, neurodegenerative, and inflammatory disorders. Along with its subsidiaries, the group is focused on pharmaceutical research and development of its compound, FSD201, an ultra-micronized PEA, for the treatment of inflammatory diseases; Lucid-Psych is used in the treatment of mental health disorders and Lucid-MS is used in the treatment of neurodegenerative disorders. The Company operates in two segments: Biotechnology and Strategic Investments.

FSD Pharma (FSD Pharma) Headlines

From GuruFocus

FSD Pharma Wins $2.8 Million Dollar Award Plus Accruing Interest from Dr. Raza Bokhari; Set Aside Motion Brought by Bokhari, Now CEO of Medicus Pharma, Dismissed by the Ontario Superior Court of Justice
By ACCESSWIRE • 10-04-2023

Goldman Small Cap Research Publishes New Research Report on FSD Pharma, Inc.
By ACCESSWIRE • 11-24-2023

FSD Pharma Inc. Obtains Final Order for Plan of Arrangement
By ACCESSWIRE • 11-27-2023

InvestmentPitch Media Video Features FSD Pharma's Definitive Agreement Granting Exclusive Rights for Launch of UNBUZZD, a Revolutionary Rapid Alcohol Detoxification Drink
By Marketwired • 08-03-2023

FSD Pharma Inc. Securityholders Approve Plan of Arrangement with Celly Nutrition Corp.
By ACCESSWIRE • 11-21-2023

Arbitration Panel Finds that Syneos Health (NASDAQ: SYNH) Failed to Use Commercially Reasonable Efforts in Conducting its Trial for FSD 201
By Business Wire • 07-17-2023

FSD Pharma Appoints Former Ontario Minister of Health Doctor Eric Hoskins to Board of Directors
By Business Wire Business Wire • 05-25-2023

FSD Pharma Rebuts Claims of GBB Drink Lab now acquired by Jupiter Wellness Inc. Trading under the symbol (NASDAQ: JUPW)
By Business Wire • 08-25-2023

InvestmentPitch Media Video Discusses FSD Pharma's Continued Development of its Exciting New Rapid Detox Drink UNBUZZD�, with Video Comments from Kevin Harrington
By Marketwired • 09-22-2023

FSD Pharma Files Preliminary Base Shelf Prospectus to Replace Expired Base Shelf Prospectus
By ACCESSWIRE • 11-07-2023

FSD Pharma Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Liabilities	Get a 7-Day Free Trial															7.83	8.60	5.85	4.20	4.57

Total Current Liabilities	=	Accounts Payable & Accrued Expense	+	Short-Term Debt & Capital Lease Obligation
	=	4.195	+	0.339
	+	Other Current Liabilities	+	Current Deferred Liabilities
	=	0.031999999999999	+	0
	=	4.57